Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Tags: , , , , ,

Related Post

Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals

  • Posted on 31 March, 2024
    Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
    Read more

    Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases

    • Posted on 25 January, 2024
      MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
      Read more

      Acoustic analysis of the effects of sustained wakefulness on speech

      • Posted on 25 January, 2024
        Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...
        Read more